Department of Pathology, University of Pittsburgh School of Medicine, UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania.
Department of Pathology, University of Pittsburgh School of Medicine, UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania.
Mod Pathol. 2024 Jul;37(7):100517. doi: 10.1016/j.modpat.2024.100517. Epub 2024 May 17.
Triple-negative breast cancer (TNBC) refers to an estrogen receptor-negative, progesterone receptor-negative, and HER2-negative breast cancer. Although accepted as a clinically valid category, TNBCs are heterogeneous at the histologic, immunohistochemical, and molecular levels. Gene expression profiling studies have molecularly classified TNBCs into multiple groups, but the prognostic significance is unclear except for a relatively good prognosis for the luminal androgen receptor subtype. Immunohistochemistry (IHC) has been used as a surrogate for basal and luminal subtypes within TNBC, but prognostication of TNBC using IHC is not routinely performed. We aimed to study immunophenotypic correlations in a well-annotated cohort of consecutive TNBCs, excluding postneoadjuvant chemotherapy cases. Tissue microarrays were constructed from a total of 245 TNBC cases. IHC stains were performed and consisted of luminal (AR and INPP4B), basal (SOX10, nestin, CK5, and EGFR), and diagnostic (GCDFP15, mammaglobin, GATA3, and TRPS1) markers. Survival analysis was performed to assess the significance of clinical-pathologic variables including age, histology, grade, lymphovascular invasion, Nottingham prognostic index category, American Joint Committee on Cancer (AJCC) stage, stromal tumor-infiltrating lymphocytes at 10% increment, CD8+ T-cell count, Ki-67 index, PD-L1 status, and chemotherapy along with the results of IHC markers. Apocrine tumors show prominent reactivity for luminal markers and GCDFP15, whereas no special-type carcinomas are often positive for basal markers. TRPS1 is a sensitive marker of breast carcinoma but shows low or no expression in apocrine tumors. High AJCC stage, lack of chemotherapy, and dual SOX10/AR negativity are associated with worse outcomes on both univariable and multivariable analyses. Lymphovascular invasion and higher Nottingham prognostic index category were associated with worse outcomes on univariable but not multivariable analysis. The staining for IHC markers varies based on tumor histology, which may be considered in determining breast origin. Notably, we report that SOX10/AR dual negative status in TNBC is associated with a worse prognosis along with AJCC stage and chemotherapy status.
三阴性乳腺癌(TNBC)是指雌激素受体阴性、孕激素受体阴性和 HER2 阴性的乳腺癌。尽管被认为是一种临床有效的分类,但 TNBC 在组织学、免疫组织化学和分子水平上具有异质性。基因表达谱研究已经将 TNBC 分子分类为多个组,但除了 luminal 雄激素受体亚型预后较好外,其预后意义尚不清楚。免疫组织化学(IHC)已被用作 TNBC 中基底和 luminal 亚型的替代物,但 TNBC 用 IHC 进行预后判断并不常规进行。我们旨在研究一个经过充分注释的连续 TNBC 队列中的免疫表型相关性,排除新辅助化疗后的病例。从总共 245 例 TNBC 病例中构建组织微阵列。进行免疫组织化学染色,包括 luminal(AR 和 INPP4B)、基底(SOX10、巢蛋白、CK5 和 EGFR)和诊断(GCDFP15、乳球蛋白、GATA3 和 TRPS1)标志物。进行生存分析,以评估包括年龄、组织学、分级、脉管侵犯、诺丁汉预后指数分类、美国癌症联合委员会(AJCC)分期、间质肿瘤浸润淋巴细胞 10%递增、CD8+T 细胞计数、Ki-67 指数、PD-L1 状态以及化疗在内的临床病理变量的意义,以及免疫组织化学标志物的结果。大汗腺癌表现出 luminal 标志物和 GCDFP15 的明显反应,而非特殊型癌通常对基底标志物呈阳性。TRPS1 是乳腺癌的敏感标志物,但在大汗腺癌中表达较低或无。高 AJCC 分期、缺乏化疗以及 SOX10/AR 双重阴性与单变量和多变量分析的较差结果相关。脉管侵犯和较高的诺丁汉预后指数分类与单变量分析但非多变量分析的较差结果相关。免疫组织化学标志物的染色根据肿瘤组织学而变化,这在确定乳房来源时可能需要考虑。值得注意的是,我们报告 TNBC 中的 SOX10/AR 双重阴性状态与 AJCC 分期和化疗状态一起与预后较差相关。